SGLT2 抑制剂在慢性肾脏病和心脏病患者中的应用：文献综述。
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review.
机构信息
Houston Methodist Hospital, Houston, Texas, US.
Weill Cornell College of Medicine, Ithaca, New York, US.
出版信息
Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):62-72. doi: 10.14797/mdcvj.1120. eCollection 2022.
Abstract
Sodium-glucose transport protein 2 inhibitors, commonly referred to as SGLT2i, are a group of prescription pharmaceuticals that are approved by the United States Food and Drug Administration for use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Diabetes is a well-recognized major contributor to cardiovascular and renal disease burden. In addition to blood glucose control, SGLT2i have been shown to provide significant cardiovascular and renoprotective benefits in patients with and without diabetes. In this review, we describe current evidence related to the renal and cardiovascular benefits of using SGLT2i.
摘要
钠-葡萄糖协同转运蛋白 2 抑制剂，通常称为 SGLT2i，是一组经美国食品和药物管理局批准的处方药，可与饮食和运动一起用于降低 2 型糖尿病成人的血糖。糖尿病是公认的导致心血管和肾脏疾病负担的主要因素之一。除了控制血糖外，SGLT2i 还已被证明在有和没有糖尿病的患者中具有显著的心血管和肾脏保护作用。在这篇综述中，我们描述了与使用 SGLT2i 相关的肾脏和心血管益处的现有证据。
相似文献
1
SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review.
Methodist Debakey Cardiovasc J. 2022 Sep 6;18(4):62-72. doi: 10.14797/mdcvj.1120. eCollection 2022.
2
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Cardiovasc Diabetol. 2022 Nov 5;21(1):232. doi: 10.1186/s12933-022-01676-5.
3
Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Cardiovasc Diabetol. 2023 Nov 16;22(1):316. doi: 10.1186/s12933-023-02023-y.
4
The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Rev Cardiovasc Med. 2022 Mar 3;23(3):82. doi: 10.31083/j.rcm2303082.
5
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Cardiovasc Diabetol. 2022 Mar 23;21(1):47. doi: 10.1186/s12933-022-01476-x.
6
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
7
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30.
8
The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
Clin Cardiol. 2020 Dec;43(12):1376-1387. doi: 10.1002/clc.23508. Epub 2020 Nov 9.
9
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
10
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
引用本文的文献
1
SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.
Cardiovasc Diabetol. 2025 Aug 31;24(1):353. doi: 10.1186/s12933-025-02874-7.
2
Enhancing therapeutic strategies and drug development for patients with kidney disease.
Expert Opin Drug Saf. 2025 Jul 4:1-26. doi: 10.1080/14740338.2025.2525970.
3
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Int J Mol Sci. 2025 Jun 14;26(12):5717. doi: 10.3390/ijms26125717.
4
Cutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.
J Clin Med. 2024 Dec 31;14(1):188. doi: 10.3390/jcm14010188.
5
Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review.
Nutrients. 2024 Nov 27;16(23):4084. doi: 10.3390/nu16234084.
6
Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases.
Front Pharmacol. 2024 Oct 30;15:1437760. doi: 10.3389/fphar.2024.1437760. eCollection 2024.
7
Emerging Therapeutic Strategies in Cardiovascular Diseases.
Cureus. 2024 Jul 12;16(7):e64388. doi: 10.7759/cureus.64388. eCollection 2024 Jul.
8
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.
Curr Issues Mol Biol. 2024 Jun 21;46(7):6300-6314. doi: 10.3390/cimb46070376.
9
Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy.
J Clin Med. 2023 Oct 16;12(20):6561. doi: 10.3390/jcm12206561.
本文引用的文献
1
Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?
Kidney360. 2021 Apr 22;2(7):1174-1178. doi: 10.34067/KID.0000732021. eCollection 2021 Jul 29.
2
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
Nat Med. 2022 Apr;28(4):809-813. doi: 10.1038/s41591-022-01703-8. Epub 2022 Feb 28.
3
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3. Epub 2021 Nov 29.
4
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28.
5
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
JAMA Netw Open. 2021 Oct 1;4(10):e2130762. doi: 10.1001/jamanetworkopen.2021.30762.
6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
7
SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis.
EClinicalMedicine. 2021 Jun 5;36:100933. doi: 10.1016/j.eclinm.2021.100933. eCollection 2021 Jun.
8
Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers.
Cureus. 2021 Mar 3;13(3):e13665. doi: 10.7759/cureus.13665.
9
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
Heart. 2021 Jun 11;107(13):1032-1038. doi: 10.1136/heartjnl-2020-318060.
10
Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly.
Eur Heart J. 2021 May 7;42(18):1739-1741. doi: 10.1093/eurheartj/ehaa1022.
Zotero 插件